TNFSF11 and melanoma: BRAFi‐treated melanoma cells co‐cultured with differentiated osteoblasts increased in cell number when compared to those co‐cultured with undifferentiated hFOB1.19 cells; an effect that was abolished by addition of a neutralizing antibody (nAb) to RANKL (Figure 5a, Figure S5a).